课题基金 / 基金详情

Developing Novel Technology for Data Driven Clinical Decision Making

Developing Novel Technology for Data Driven Clinical Decision Making
开发数据驱动临床决策的新技术
批准号:
MR/Y007816/1
负责人:
Lauren Ford
金额:
$66.04万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Glioblastoma (GBM) brain tumours are deadly and incurable. Effective treatment options for GBM are urgently needed. The extent of surgical GBM tumour resection substantially positively impacts patient survival, but damage to normal brain tissue can severely affect quality of life and hence must be minimised. Therefore, it is imperative that we develop tools for surgical removal which can:A) precisely remove cancer cells, with reduced thermal impact on normal brain cells B) give feedback at the time of resection to surgeons so that they know which areas of the brain tissue are malignant and need to be removed and C) give doctors indications of the nature of the cancer so that the most effective therapy can be employed post-operatively for any cancer cells left behind. Development of this technology would be instrumental to revolutionising the way surgeons treat cancer. To do this we will develop high-precision lasers and understand their effects on tissue using very high-definition cameras, we will then collect the 'smoke' produced by these lasers when cutting and feed it into a mass spectrometer which is capable of measuring all of the individual metabolite chemicals representative of the tissue it has come from. When cancer is present, cells metabolise differently and hence this can be measured using the technology described. Observing the changes in metabolism can help us to understand complex diseases such as cancer and the therapies which may be effective against them. Therefore, in this project we will take the data from our novel technology and use machine learning to understand changes in the chemical compositions of the tissues and how that correlates to the different subtypes of cancer and use this information to predict the nature of any recurrent disease. If we can predict the recurrent nature of disease from the primary tissue, we may be able to use therapies more effectively to stop recurrence altogether.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: